Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Systemic Therapy + Cytoreductive Prostatectomy in de Novo pmHSPC
NCT06306612Recruiting
- Sponsor
- Renji Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in prostate cancer (PCa) (2 arms), sponsored by Renji Hospital. Primary endpoint: Castration resistant-free survival at 3 years. Started Mar 2024; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06306612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306612.